Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice

Angiogenesis

Volumn 8, Issue 4, 2006, Pages 339-348

  Axelsson, Hans ^a   Lönnroth, Christina ^a   Wang, Wenhua ^a   Svanberg, Elisabeth ^a   Lundholm, Kent ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Angiogenesis; COX; EP subtype receptor; Gene knockout

Indexed keywords

INDOMETACIN; MESSENGER RNA; PROSTAGLANDIN SYNTHASE;

ADAPTATION; ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; ATTENUATION; CELL GROWTH; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENSITY; DRUG EFFECT; ENZYME INHIBITION; GROWTH RATE; HUMAN; HYPOXIA; IMMUNOHISTOCHEMISTRY; MOUSE; MOUSE STRAIN; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; TUMOR; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; WILD TYPE;

ANIMALS; CELL LINE, TUMOR; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; INDOMETHACIN; MELANOMA; MEMBRANE PROTEINS; MICE; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, KNOCKOUT; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, PROSTAGLANDIN E;

ANIMALIA;

EID: 33644604416     PISSN: 09696970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10456-005-9023-8     Document Type: Article

References (51)

1. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182-6.
2. Gasparini G, Longo R, Fanelli M, Teicher BA. Combination of antiangiogenic therapy with other anticancer therapies: Results, challenges, and open questions. J Clin Oncol 2005; 23: 1295-311.
3. Peterson HI. Tumor angiogenesis inhibition by prostaglandin synthetase inhibitors. Anticancer Res 1986; 6: 251-3.
4. Wang HM, Zhang GY. Indomethacin suppresses growth of colon cancer via inhibition of angiogenesis in vivo. World J Gastroenterol 2005; 11: 340-3.
5. Cahlin C, Korner A, Axelsson H et al. Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon-gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Res 2000; 60: 5488-93.
6. Peluffo GD, Stillitani I, Rodriguez VA et al. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 2004; 110: 825-30.
7. McMillan DC, Leen E, Smith J et al. Effect of extended ibuprofen administration on the acute phase protein response in colorectal cancer patients. Eur J Surg Oncol 1995; 21: 531-4.
8. Gelin J, Andersson C, Lundholm K. Effects of indomethacin, cytokines, and cyclosporin A on tumor growth and the subsequent development of cancer cachexia. Cancer Res 1991; 51: 880-5.
9. Cahlin C, Gelin J, Delbro D et al. Effect of cyclooxygenase and nitric oxide synthase inhibitors on tumor growth in mouse tumor models with and without cancer cachexia related to prostanoids. Cancer Res 2000; 60: 1742-9.
10. Lönnroth C, Svaninger G, Gelin J et al. Effects related to indomethacin prolonged survival and decreased tumor growth in a mouse tumor model with cytokine dependent cancer cachexia. Int J Oncol 1995; 7: 1405-13.
11. Lundholm K, Gelin J, Hyltander A et al. Anti-inflammatory treatment may prolong survival in undernourished patients with metastatic solid tumors. Cancer Res 1994; 54: 5602-6.
12. Lundholm K, Daneryd P, Korner U et al. Evidence that long-term COX-treatment improves energy homeostasis and body composition in cancer patients with progressive cachexia. Int J Oncol 2004; 24: 505-12.
13. Rajendran JG, Krohn KA. Imaging hypoxia and angiogenesis in tumors. Radiol Clin North Am 2005; 43: 169-87.
14. Cahlin C. Gelin J, Andersson M et al. The effects of non-selective, preferential-selective and selective COX-inhibitors on the growth of experimental and human tumors in mice related to prostanoid receptors. Int J Oncol 2005; 27: 913-23.
15. Lönnroth C, Andersson M, Lundholm K. Indomethacin and telomerase activity in tumor growth retardation. Int J Oncol 2001; 18: 929-37.
16. Ushikubi F, Segi E, Sugimoto Y et al. Impaired febrile response in mice lacking the prostaglandin E receptor subtype EP3. Nature 1998; 395: 281-4.
17. Batshake B, Sunderin J. The mouse genes for the EP1 prostanoid receptor and the PKN protein kinase overlap. Biochem Biophys Res Commun 1996; 227: 70-6.
18. Wang W, Andersson M, Lönnroth C et al. Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. J Exp Clin Cancer Res 2005; 24: 99-107.
19. Axelsson H, Bagge U, Lundholm K, Svanberg E. A one-piece plexiglass access chamber for subcutaneous implantation in the dorsal skin fold of the mouse. Int J Microcirc Clin Exp 1997; 17: 328-9.
20. Sales KJ, Katz AA, Howard B et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: Autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 2002; 62: 424-32.
21. Needleman P, Turk J, Jakschik BA et al. Arachidonic acid metabolism. Annu Rev Biochem 1986; 55: 69-102.
22. Halushka PV, Mais DE, Mayeux PR, Morinelli TA. Thromboxane, prostaglandin and leukotriene receptors. Annu Rev Pharm Tox 1989; 10: 213-39.
23. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest 2001; 108: 25-30.
24. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 1998; 90: 1529-36.
25. Watson AJ. Chemopreventive effects of NSAIDs against colorectal cancer: Regulation of apoptosis and mitosis by COX-1 and COX-2. Histol Histopathol 1998; 13: 591-7.
26. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1α and HIF-2α in prostate cancer cells. Clin Cancer Res 2003; 9: 3150-7.
27. Kragh M, Hjarnaa PJ, Bramm E et al. In vivo chamber angiogenesis assay: An optimized Matrigel plug assay for fast assessment of anti-angiogenic activity. Int J Oncol 2003; 22: 305-11.
28. Raut CP, Nawrocki S, Lashinger LM et al. Celecoxib inhibits angiogenesis by inducing endothelial cell apoptosis in human pancreatic tumor xenografts. Cancer Biol Ther 2004; 3.
29. Jones MK, Wang H, Peskar BM et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med 1999; 5: 1418-23.
30. Castro MR, Lutz D, Edelman JL. Effect of COX inhibitors on VEGF-induced retinal vascular leakage and experimental corneal and choroidal neovascularization. Exp Eye Res 2004; 79: 275-85.
31. Pearce HR, Kalia N, Bardhan KD, Brown NJ. Effects of aspirin and indomethacin on endothelial cell proliferation in vitro. J Gastroenterol Hepatol 2003; 18: 1180-7.
32. Szabo IL, Pai R, Soreghan B et al. NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis? J Physiol Paris 2001; 95: 379-83.
33. Davel LE, Rimmaudo L, Espanol A et al. Different mechanisms lead to the angiogenic process induced by three adenocarcinoma cell lines. Angiogenesis 2004; 7: 45-51.
34. Chen JJ, Yao PL, Yuan A et al. Up-regulation of tumor interleukin-8 expression by infiltrating macrophages: Its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Cancer Res 2003; 9: 729-37.
35. Golab J, Kozar K, Kaminski R et al. Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice. Life Sci 2000; 66: 1223-30.
36. Lala PK, Al-Mutter N, Orucevic A. Effects of chronic indomethacin therapy on the development and progression of spontaneous mammary tumors in C3H/HEJ mice. Int J Cancer 1997; 73: 371-80.
37. Spisni E, Manica F, Tomasi V. Involvement of prostanoids in the regulation of angiogenesis by polypeptide growth factors. Prostaglandins Leukot Essent Fatty Acids 1992; 47: 111-5.
38. Chang SH, Liu CH, Conway R et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci USA 2004; 101: 591-6.
39. Gallo O, Franchi A, Magnelli L et al. Cyclooxygenase-2 pathway correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. Neoplasia 2001; 3: 53-61.
40. Pai R, Szabo IL, Kawanaka H et al. Indomethacin inhibits endothelial cell proliferation by suppressing cell cycle proteins and PRB phosphorylation: A key to its antiangiogenic action? Mol Cell Biol Res Commun 2000; 4: 111-6.
41. Li G, Yang T, Yan J. Cyclooxygenase-2 increased the angiogenic and metastatic potential of tumor cells. Biochem Biophys Res Commun 2002; 299: 886-90.
42. Sawaoka H, Tsuji S, Tsujii M et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab Invest 1999; 79: 1469-77.
43. Fosslien E. Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000; 37: 431-502.
44. Watanabe K, Kawamori T, Nakatsugi S et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Cancer Res 1999; 59: 5093-6.
45. Franzese O, Comandini A, Cannavo E et al. Effect of prostaglandin A1 on proliferation and telomerase activity of human melanoma cells in vitro. Melanoma Res 1998; 8: 323-8.
46. Ogino M, Hisatomi H, Murata M, Hanazono M. Indomethacin suppresses the growth of colon 26, Meth-A and FM3A tumors in mice by reducing the prostaglandin E2 content and telomerase activity in tumor tissues. Jpn J Cancer Res 1999; 90: 758-64.
47. You BJ, Huang U, Liu WH et al. Decrease in nucleophosmin/B23 mRNA and telomerase activity during indomethacin-induced apoptosis of gastric KATO-III cancer cells. Naunyn Schmiedebergs Arch Pharmacol 1999; 360: 683-90.
48. Amano H, Hayashi I, Endo H et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med 2003; 197: 221-32.
49. Takafuji V, Cosme R, Lublin D et al. Prostanoid receptors in intestinal epithelium: Selective expression, function, and change with inflammation. Prostaglandins Leukot Essent Fatty Acids 2000; 63: 223-35.
50. Dirkx AE, Oude Egbrink MG, Kuijpers MJ et al. Tumor angiogenesis modulates leukocyte-vessel wall interactions in vivo by reducing endothelial adhesion molecule expression. Cancer Res 2003; 63: 2322-9.
51. Fukumura D, Salehi HA, Witwer B et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: Effect of tumor type, transplantation site, and host strain. Cancer Res 1995; 55: 4824-9.